Civica said yesterday it expects to launch lower-cost versions of insulin in the US by 2024, to help diabetic patients struggling with high prices for the life-sustaining medicine.
Civica, launched in 2018 to make generic drugs, said it would produce three copycat versions of insulin, and make them available at roughly the same price for all customers, once approved by the US health regulators.
The company’s products, which would be available as both vials and pre-filled pens, are biosmilars to Sanofi SA’s Lantus, Eli Lilly and Co’s Humalog and Novo Nordisk’s Novolog.
The maximum price for all three of Civica’s products would be no more than $30 per vial and no more than $55 for a box of five pen cartridges, the company said.
That compares with $300 per vial and $500 for five pens, which are the average wholesale prices, according to Civica.
Sanofi, Lilly and Novo Nordisk have long dominated the US diabetes market, but face growing pressure from lawmakers on why the cost of the nearly 100-year-old medication had rapidly risen.
In response, Eli Lilly in 2019 launched its own cut-price versions of Humalog, while Sanofi said it would cut the cost of its insulin products for some US patients. Novo also offers a generic version of Novolog at a 50 per cent discount.
Civica, which was launched by seven health systems including HCA Healthcare and Mayo Clinic to make essential medicines available at affordable prices, is launching clinical studies for its insulins this year and expects to file for regulatory approval in 2023.
It estimates that the first product would be available for purchase by early 2024.
We are honored to invite you to be the speaker at “27th World Conference & Expo On Dermatology “Which is Scheduled to happen on April 13th to 14th, 2022 at Perth, Australia. This event will be exploring new ideas and researching Dermatology.
We look forward to positive confirmation any kind of information about the conference event Kindly drop a mail to us